do you need a prescription for glp 1 drugs GLP-1 Updates Employers: Demand, Shortages, and Cost Do You Need a Prescription

J Biotechnol 150(4):519529

In addition, similar to our discussion in the FY 2021 IPPS/LTCH PPS final rule (85 FR 58886 through 58887), in the CY 2026 OPPS/ASC proposed rule we stated that, if the proposed policy were finalized, we would intend to provide additional opportunity for the public to review the MAO median payer-specific negotiated charge data received prior to the utilization of this data in the market-based MS-DRG relative weight methodology beginning in FY 2029

Clinical utility of dipeptidyl peptidase-4 inhibitors: A descriptive summary of current efficacy trials

Similar to the effects associated with the STEMI eCQM finalized for the Hospital OQR Program in the CY 2022 OPPS/ASC final rule with comment period (86 FR 63984 and 63985), we believe that costs associated with adoption of eCQMs are multifaceted and include not only the burden associated with reporting but also the costs associated with implementing and maintaining program requirements, such as maintaining measure specifications in REHs' EHR systems for the eCQMs used in the REHQR Program